> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA 6-Month PREPP Initiative Report
- URL: https://www.fdaweb.com/fda-6-month-prepp-initiative-report/
- Published: 2021-01-14T12:00:00.000Z
- Updated: 2026-09-14T16:42:43.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5148452

FDA has issued a report, *FDA Covid-19 Pandemic Recovery and Preparedness Plan (PREPP) Initiative: Summary Report*, summarizing the insights, supporting facts, and work of the FDA Covid-19 PREPP initiative between 7/2020 and 12/2020\. The [report](https://www.fda.gov/media/145129/download?ref=fdaweb.com) describes ongoing and potential prospective actions to strengthen the agency’s Covid-19 response and build the agency’s resilience to respond to future emergencies. It does not offer a retrospective assessment of FDA’s Covid-19 response, it says.

According to the report, PREPP has been focused on identifying options for, and selectively progressing, prospective enterprise-wide response and resilience actions, including programmatic, process, and organizational initiatives.

FDA actions cited in the report include: 

- publishing more than 65 guidances relating to Covid-19;
- reviewing over 2,300 emergency use authorization requests and issuing over 600 emergency use authorizations;
- reviewing and conducting inspection activities for nearly 400 Covid-19 therapeutic candidates; and
- issuing over 150 Warning Letters to companies to enforce the safety and quality of Covid-19 related products and preventing or removing more than 1,200 fraudulent Covid-19 products from the market.